Готові списки джерел за темами / Sofosbuvir And Daclatasvir

Зміст

Статті в журналах
Дисертації
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Sofosbuvir And Daclatasvir"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Sofosbuvir And Daclatasvir".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Sofosbuvir And Daclatasvir"

Sacramento, Carolina Q., Natalia Fintelman-Rodrigues, Jairo R. Temerozo, et al. "In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19." Journal of Antimicrobial Chemotherapy 76, no. 7 (2021): 1874–85. http://dx.doi.org/10.1093/jac/dkab072.

Повний текст джерела

Анотація:

Abstract Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity. Methods SARS-CoV-2-infected

Стилі APA, Harvard, Vancouver, ISO та ін.

Chakravarthy, V. Ashok, Sailaja Bbv, and Praveen Kumar A. "METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR IN ACTIVE PHARMACEUTICAL INGREDIENT FORM." Asian Journal of Pharmaceutical and Clinical Research 9, no. 9 (2016): 61. http://dx.doi.org/10.22159/ajpcr.2016.v9s3.14616.

Повний текст джерела

Анотація:

ABSTRACTObjective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitativeestimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir in its active pharmaceutical ingredient (API) form.Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir isbased on measurement of absorption at a wavelength maximum (λmax) of 317 and 261 nm using methanol as solvent.Results: The method was validated in terms of specificity, precision, linearity, a

Стилі APA, Harvard, Vancouver, ISO та ін.

C. Damle, Mrinalini, and Nivedita B. Pawar. "STABILITY INDICATING HPLC METHOD FOR SOFOSBUVIR AND DACLATASVIR IN COMBINATION." Indian Drugs 59, no. 10 (2022): 74–79. http://dx.doi.org/10.53879/id.59.10.12506.

Повний текст джерела

Анотація:

Direct acting fixed dose combination of sofosbuvir and daclatasvir to treat the viral hepatitis C disease is available in the market. So, a precise and robust stability indicating HPLC method for sofosbuvir and daclatasvir was developed. The SunQ C18 column (250 x 4.6 mm) was used for chromatographic separation with mobile phase consisting of 0.03 mM potassium dihydrogen phosphate buffer (pH 7): ACN (50: 50V/V). Optimised method satisfies the system suitability parameters with good resolution with 4.9 min Rt of sofosbuvir and 7.6 min Rt of daclatasvir. The method was validated as per ICH guide

Стилі APA, Harvard, Vancouver, ISO та ін.

Ahmad Ather, Ch Adnan, Mariyam Nawaz, Sohail Bashir Sulehria, Saadia Chaudary, Zara Mehmood, and Maria Rehman. ""TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OFHEPATITIS C VIRUS"." Journal of Akhtar Saeed Medical & Dental College 05, no. 02 (2023): 90–96. https://doi.org/10.51127/jamdcv5i2oa05.

Повний текст джерела

Анотація:

Background:To compare the frequency of responders achieving SVR12 after taking sofosbuvir and daclatasvir with vs without ribavirin.Material and Methods:Total 180 patients meeting inclusion criteria were enrolled in the studyfromDepartment of Medicine, Government Teaching Hospital Shahdara, Lahore.This randomized controlled trial was conducted fromMarch 25, 2021,to September 24, 2021.Treatment naive cases were given tablet sofosbuvir & daclatasvir for 12 weeks. Treatment-experienced and naive with cirrhosis were given ribavirin based on their body weight along with sofosbuvir and daclatasv

Стилі APA, Harvard, Vancouver, ISO та ін.

Mobarak, Sara, Mehdi Salasi, Ahmad Hormati, et al. "Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)." Journal of Antimicrobial Chemotherapy 77, no. 3 (2021): 758–66. http://dx.doi.org/10.1093/jac/dkab433.

Повний текст джерела

Анотація:

Abstract Background The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical outcomes in hospitalized patients with COVID-19. Methods This was a placebo-controlled, double-blind, randomized clinical trial in adults hospitalized with COVID-19 at 19 hospitals in Iran. Patients were randomized to oral sofosbuvir/daclatasvir 400/60 mg once-daily or placebo in addition to standar

Стилі APA, Harvard, Vancouver, ISO та ін.

Eslami, Gholamali, Sajedeh Mousaviasl, Esmat Radmanesh, et al. "The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19." Journal of Antimicrobial Chemotherapy 75, no. 11 (2020): 3366–72. http://dx.doi.org/10.1093/jac/dkaa331.

Повний текст джерела

Анотація:

Abstract Objectives Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19. Methods Patients with a positive nasopharyngeal swab for SARS-CoV-2 on RT–PCR or bilateral multi-lobar ground-glass opacity on their chest CT and signs of severe COVID-19 were included. Subjects were divided into two arms with one arm receiving

Стилі APA, Harvard, Vancouver, ISO та ін.

Hessel, Marleen H. M., Adam F. Cohen, and Robert Rissmann. "Sofosbuvir and daclatasvir." British Journal of Clinical Pharmacology 82, no. 3 (2016): 878–79. http://dx.doi.org/10.1111/bcp.13011.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Abdelaty, Lamiaa N., Ahmed A. Elnaggar, Amira A. Said, and Raghda R. S. Hussein. "Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients." Current Drug Safety 15, no. 1 (2020): 53–60. http://dx.doi.org/10.2174/1574886314666191001151314.

Повний текст джерела

Анотація:

Background: Chronic Hepatitis C (CHC) is a common progressive healthcare challenge that leads to liver cirrhosis, liver failure, and hepatocellular carcinoma. The optimum therapy was a combination of pegylated interferon and ribavirin, which was associated with moderate response and severe side effects. Sofosbuvir revolutionized CHC treatment, especially in combination with other antiviral agents. Objective: The aim of this study was to compare and evaluate the safety and efficacy of sofosbuvir/ daclatasvir versus sofosbuvir/ledipasvir for the treatment of non-cirrhotic naïve patients with chr

Стилі APA, Harvard, Vancouver, ISO та ін.

Damle, Mrinalini, and Nivedita Pawar. "Stability Indicating HPTLC Method for Sofosbuvir and Daclatasvir in Combination." International Journal of Pharmaceutical Sciences and Nanotechnology 13, no. 6 (2020): 5234–42. http://dx.doi.org/10.37285/ijpsn.2020.13.6.8.

Повний текст джерела

Анотація:

Direct acting antiviral agents represent the major advance in treatment of hepatitis C virus (HCV) infection. Daclatasvir with sofosbuvir that are co-administrated once per day oral dose has been reported to achieve a high rate of virological response in patients with HCV genotype 1, 2 or 3. So, the basic objective of a research involved development and validation of stability indicating HPTLC Method for simultaneous estimation of Sofosbuvir and Daclatasvir available in market in the form of combination tablet. Samples were applied on HPTLC aluminium plates precoated with silica gel 60 F254 (2

Стилі APA, Harvard, Vancouver, ISO та ін.

Sangani, Monika, and Nirav V. Patel. "STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS DETERMINATION OF SOFOSBUVIR AND DACLATASVIR IN TABLET DOSAGE FORM." Indian Drugs 59, no. 11 (2022): 73–80. http://dx.doi.org/10.53879/id.59.11.13047.

Повний текст джерела

Анотація:

New stability indicating RP-HPLC method for the simultaneous estimation of sofosbuvir and daclatasvir in its pharmaceutical dosage form was developed and validated. Column used was PhenomenexC18 (150mm x 4.6mm, 5µ) with mobile phase water and acetonitrile (50:50 V/V) in isocratic mode. Flow rate of mobile phase 1.0mL min-1 and column oven temperature were maintained at 30o C. Sofosbuvir and daclatasvir were detected at a wavelength 230nm. The retention times for sofosbuvir and daclatasvir were found to be 3.06 min and 4.76 min, respectively. Validation of the method was done according to ICH g

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Sofosbuvir And Daclatasvir"

BARROS, Luciana Tavares de Carvalho. "Avaliação da eficácia e segurança do daclatasvir e sofosbuvir versus alfapeginterferona 2A no tratamento da hepatite C crônica." Universidade Federal de Pernambuco, 2016. https://repositorio.ufpe.br/handle/123456789/24772.

Повний текст джерела

Анотація:

Submitted by Alice Araujo (alice.caraujo@ufpe.br) on 2018-06-05T18:24:22Z No. of bitstreams: 1 DISSERTAÇÃO Luciana Tavares de Carvalho Barros.pdf: 978217 bytes, checksum: 9bbd97bc0d108d6999496e25f30b47df (MD5) Made available in DSpace on 2018-06-05T18:24:22Z (GMT). No. of bitstreams: 1 DISSERTAÇÃO Luciana Tavares de Carvalho Barros.pdf: 978217 bytes, checksum: 9bbd97bc0d108d6999496e25f30b47df (MD5) Previous issue date: 2016-06-09 A Hepatite C representa um grande impacto na saúde pública em todo o mundo. Interfere na vida dos portadores de HCV, na sociedade, no sistema de saúde e n

Стилі APA, Harvard, Vancouver, ISO та ін.

Jarek, Nayara Almeida de Assis. "Análise de custo-efetividade do tratamento precoce da hepatite viral C crônica com simeprevir, daclatasvir e sofosbuvir sob a perspectiva do Sistema Único de Saúde." reponame:Repositório Institucional da UFPR, 2017. http://hdl.handle.net/1884/53663.

Повний текст джерела

Анотація:

Orientador : Prof. Dr. Roberto Pontarolo Coorientadora : Drª. Inajara Rotta Dissertação (mestrado) - Universidade Federal do Paraná, Setor de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas. Defesa: Curitiba, 22/09/2017 Inclui referências : f. 83-93 Resumo: A hepatite viral C crônica é causada pelo vírus da hepatite C (VHC) e os indivíduos são considerados curados após atingir a resposta virológica sustentada (RVS). Porém, os elevados custos dificultam o acesso às terapias disponíveis. Dados os recursos limitados, a inserção de novas terapias deve ter sua via

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Sofosbuvir And Daclatasvir"

VOLKWEIS, J. G., A. C. C. SANCHES, O. D. BOEIRA JUNIOR, and J. A. D. HORVATH. "AVALIAÇÃO DO USO E ANÁLISE DE CUSTOS DOS MEDICAMENTOS SOFOSBUVIR, SIMEPREVIR, DACLATASVIR PARA TRATAMENTO DA HEPATITE VIRAL CRÔNICA TIPO C DO COMPONENTE ESPECIALIZADO DA ASSISTÊNCIA FARMACÊUTICA NO MUNICÍPIO DE CASCAVEL - PR." In Diálogos entre Enfermagem e Farmácia: – Volume 1. Dialética, 2023. http://dx.doi.org/10.48021/978-65-270-0772-2-c4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Sofosbuvir And Daclatasvir"

Pajin, R. Madera, R. Asensi Diez, L. Yunquera Romero, JC Del Rio Valencia, and I. Muñoz Castillo. "DI-044 Effectiveness of the combination sofosbuvir and daclatasvir for the treatment of hepatitis C virus infection." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.291.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Sofosbuvir And Daclatasvir"

Hung, Hsuan-Yu, Hui-Hsiung Lai, Hui-Chuan Lin, and Chung-Yu Chen. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0055.

Повний текст джерела

Анотація:

Review question / Objective: P: ("Hepatitis C"[Mesh] AND "Hepacivirus"[Mesh] AND "Hepatitis C, Chronic”[Mesh]) I: (direct acting antiviral OR asunaprevir OR boceprevir OR daclatasvir OR dasabuvir OR elbasvir OR glecaprevir OR grazoprevir OR ledipasvir OR ombitasvir OR paritaprevir OR pibrentasvir OR simeprevir OR sofosbuvir OR telaprevir OR velpatasvir OR voxilaprevir) C: placebo O: ( "Cholesterol, VLDL"[Mesh] OR "Cholesterol, LDL"[Mesh] OR "Cholesterol, HDL"[Mesh] OR "Dyslipidemias"[Mesh] OR "lipoprotein cholesterol ester, human" [Supplementary Concept] OR "lipoprotein cholesterol" [Supplemen

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!